BOONTON, N.J.--(BUSINESS WIRE)--Nov. 5, 2008--Unigene
Laboratories, Inc. (OTCBB: UGNE, http://www.unigene.com) will release
financial results for the third quarter ended September 30, 2008,
after the market closes on Monday, November 10, 2008. The Company will
also host a conference call the next morning, Tuesday, November 11th
at 9:00 AM EDT, to discuss its third quarter 2008 financial results
and to provide a Company update.
Unigene invites all those interested in hearing management's
discussion to join the call by dialing 877-407-0782 for participants
in the United States and 201-689-8567 for international participants.
A replay will be available for seven days after the call and can be
accessed by dialing 877-660-6853 for participants in the United States
and 201-612-7415 for international participants. When prompted, enter
account #286 and conference ID #301594. The conference call may also
be accessed via the Web at http://www.unigene.com and a link will be
provided for listeners to join the call.
About Unigene
Unigene Laboratories, Inc. is a biopharmaceutical company focusing
on the oral and nasal delivery of large-market peptide drugs. Due to
the size of the worldwide osteoporosis market, Unigene is targeting
its initial efforts on developing calcitonin and PTH-based therapies.
Fortical(R), Unigene's nasal calcitonin product for the treatment of
postmenopausal osteoporosis, received FDA approval and was launched in
August 2005. Unigene has licensed the U.S. rights for Fortical(R) to
Upsher-Smith Laboratories, worldwide rights for its oral PTH
technology to GlaxoSmithKline and worldwide rights for its calcitonin
manufacturing technology to Novartis. Unigene's patented oral delivery
technology has successfully delivered, in preclinical and/or clinical
trials, various peptides including calcitonin, PTH and insulin.
Unigene's patented manufacturing technology is designed to
cost-effectively produce peptides in quantities sufficient to support
their worldwide commercialization as oral or nasal therapeutics. For
more information about Unigene, call (973) 265-1100 or visit
www.unigene.com. For information about Fortical, visit
www.fortical.com.
Safe Harbor statements under the Private Securities Litigation
Reform Act of 1995: This press release contains forward-looking
statements as defined in Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. Such forward-looking statements are based upon Unigene
Laboratories, Inc.'s management's current expectations, estimates,
beliefs, assumptions, and projections about Unigene's business and
industry. Words such as "anticipates," "expects," "intends," "plans,"
"predicts," "believes," "seeks," "estimates," "may," "will," "should,"
"would," "potential," "continue," and variations of these words (or
negatives of these words) or similar expressions, are intended to
identify forward-looking statements. In addition, any statements that
refer to expectations, projections, or other characterizations of
future events or circumstances, including any underlying assumptions,
are forward-looking statements. These forward-looking statements are
not guarantees of future performance and are subject to certain risks,
uncertainties, and assumptions that are difficult to predict.
Therefore, our actual results could differ materially and adversely
from those expressed in any forward-looking statements as a result of
various risk factors. These risks and uncertainties include the risks
associated with the effect of changing economic conditions, trends in
the products markets, variations in Unigene's cash flow, market
acceptance risks, technical development risks and other risk factors
detailed in Unigene's Securities and Exchange Commission filings.
CONTACT: Investors:
The Investor Relations Group
Erika Moran/Dian Griesel, PhD, 212-825-3210
or
Media:
Janet Vasquez, 212-825-3210
SOURCE: Unigene Laboratories, Inc.
|
